Genzyme Seeks Toss Of Investors' Insider Trading Suit

Law360, New York (February 1, 2011, 7:28 PM EST) -- Genzyme Corp. has asked a federal judge to dismiss a shareholder suit that accuses company executives of misleading the U.S. Food and Drug Administration and selling $117 million worth of stock based on nonpublic information.

The biotech giant said that its board of directors has already responded to the shareholders’ allegations and found no evidence of wrongdoing by the defendants in a motion filed on Monday in the U.S. District Court for the District of Massachusetts.

The shareholders claim that the defendants — Genzyme CEO Henri...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re GENZYME CORP. DERIVATIVE LITIGATION


Case Number

1:09-cv-12170

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

George A. OToole, Jr

Date Filed

December 22, 2009

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.